Cidara Therapeutics (CDTX) stock is soaring 5.87% in pre-market trading on Friday, buoyed by a series of positive analyst ratings and an increased price target. The biotechnology company, known for its antifungal and antiviral therapeutics, is seeing renewed investor interest following these upbeat assessments.

Needham analyst Joseph Stringer has reiterated a Buy rating on Cidara Therapeutics and significantly raised the price target from $100 to $135. This upgrade comes on the heels of Stringer's positive outlook on the company's progress in its CD388 Flu Program and strategic trial advancements. Additionally, H.C. Wainwright analyst Sara Nik has also maintained a Buy rating on the stock, with an even more optimistic price target of $150.

These bullish analyst views are likely driven by Cidara's recent developments in its drug pipeline, particularly the advancements in its influenza prevention program. As the company continues to make strides in its clinical trials and strategic initiatives, investors appear to be gaining confidence in Cidara's potential for future growth and success in the competitive biotechnology sector. The stock's sharp rise reflects the market's positive reaction to these analyst upgrades and the company's promising outlook.